August 1, 2022

Lung Cancer Screening Entails More Than CT Scans (Podcast)

High-quality programs help ensure that screening – now considered standard of care – is done right

In 2021, the U.S. Preventive Services Task Force expanded its eligibility for lung cancer screening to encompass adults aged 50 to 80 years old who have a 20-pack-year smoking history and currently smoke or have quit within the past 15 years. The change is science-based, taking into consideration research such as the NELSON Study that showed reduced lung cancer mortality with low-dose CT screening.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The bottom line is absolutely there’s mortality benefit from screening,” says Peter Mazzone, MD, MPH, Director of the Lung Cancer Program and Lung Cancer Screening Program in Cleveland Clinic’s Respiratory Institute. “Lung cancer screening should now be considered standard of care.”

In a featured episode of Cleveland Clinic’s Respiratory Exchange podcast, Dr. Mazzone talks about lung cancer screening, including:

  • The difference between screening and diagnostic testing.
  • Potential harms of low-dose CT scan for screening.
  • Advice for launching a lung cancer screening program.
  • The importance of generating awareness and knowledge about screening among the provider community.
  • The future of lung cancer screening, including new screening algorithms and population management systems.

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Respiratory Exchange episodes at my.clevelandclinic.org/podcasts/respiratory-exchange or wherever you get your podcasts.

Excerpt from the podcast

Podcast host Raed Dweik, MD, MBA: You’ve spent a lot of time and energy building our lung cancer screening program here. Can you share with our audience … what it takes to establish a lung cancer screening program?

Advertisement

Dr. Mazzone: I like the question because you use the word “program.” … Screening is not just a test here. It is a program. An what’s most important is that the programs are designed to provide really high-quality care. You’re screening the right individuals; you’re using proper imaging techniques. You’re talking to patients about the benefits and harms, letting them make informed decisions about whether to participate.

You have systems in place to manage the findings from the scan, whether it be the lung nodules we talked about or anything else that’s imaged on the chest. You have systems in place to help patients adhere to follow-up recommendations and to the annual scan.

In general, the design of the program only matters in that you have to meet each of those components of high-quality screening that I listed. And in general, the design can be divided into a centralized program or a decentralized program.

Centralized means a provider refers someone to the program, and the program does the rest. They talk to the patient, do the scan, interpret it and manage the findings. Decentralized would be the entire opposite. The primary provider talks to the patient, identifies the right patients, orders the test and then manages all the findings.

Advertisement

One system isn’t necessarily right or wrong; it depends on where you’re practicing and what your resources are. But what’s critical is that each of those components is present.

In general, in the literature, it’s been shown that a centralized program is more likely to screen the proper population; they have better adherence to follow-up recommendations and annual screening. And so we certainly favor centralized screening. But we also have to recognize that every place that has patients eligible doesn’t have the same resources to develop that.

In that situation, I’d suggest connecting or combining with larger health systems, regionally or nationally, to help make sure that you’re checking all the boxes – that you have all these components in place.

Related Articles

Cleveland Clinic physiatrist
March 22, 2024
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

Ad